Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioArctic | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 24.06B | 26.6x | 0.03 | SEK 271.40 | 15.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.9% Upside | Upgrade to Pro+ | |
Alvotech DRC | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 23.90B | 38.9x | 0.38 | SEK 78.04 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intellego Technologies AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 4.46B | 18.3x | 0.82 | SEK 154 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.3% Upside | Upgrade to Pro+ | |
Cereno Scientific | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.94B | -28.2x | 0.4 | SEK 10.46 | 8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hansa Biopharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.71B | -3.7x | -0.12 | SEK 32.02 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vicore Pharma Holding AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.60B | -5.9x | 1.77 | SEK 11.02 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Devyser Diagnostics AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.42B | -53x | -3.14 | SEK 147.80 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | |
BioInvent International | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 2.19B | -4.7x | 0.13 | SEK 33.35 | -7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Saniona AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.93B | 7.2x | 0.03 | SEK 13.94 | 13.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -11.1% Downside | Upgrade to Pro+ | |
Egetis Therapeutics AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.90B | -5.7x | -0.26 | SEK 5.29 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
XSpray Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.63B | -6.2x | 2.61 | SEK 43.80 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Diamyd Medical | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.55B | -6.7x | 0.94 | SEK 11.30 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oncopeptides | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 1.07B | -3.8x | 1.18 | SEK 4.74 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19% Upside | Upgrade to Pro+ | |
Hamlet Pharma AB | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 1.03B | -24.5x | -1.66 | SEK 5.79 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SynAct Pharma AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 971.17M | -8.9x | -0.19 | SEK 18.34 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.8% Upside | Upgrade to Pro+ | |
Nanoform Finland Plc | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 870.33M | -3.3x | -0.67 | SEK 9.55 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cantargia AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 641.42M | -3.3x | -0.1 | SEK 2.57 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascelia Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 549.96M | -4.4x | -0.14 | SEK 4.74 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.9% Upside | Upgrade to Pro+ | |
Guard Therapeutics | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 447.72M | -2.5x | 0.26 | SEK 22.20 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xbrane Biopharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 398.37M | -2.5x | -0.03 | SEK 0.26 | -12.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mendus AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 380.22M | -3.4x | -0.09 | SEK 7.30 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intervacc | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 344.22M | -1.4x | -0.1 | SEK 1.01 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AlzeCure Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 319.63M | -8.6x | -0.32 | SEK 3.63 | -9.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Promimic AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 295.66M | -25.1x | 0.5 | SEK 14.50 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xintela | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 256.33M | -6x | -0.16 | SEK 0.38 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Curasight AS | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 244.21M | -2.8x | 0.72 | SEK 6.24 | 7.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bio-Works | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 232.27M | -6x | -0.12 | SEK 2.89 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Initiator Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 230M | -12x | -0.97 | SEK 3.49 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medivir B | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 219.85M | -1.8x | -0.08 | SEK 1.96 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Active Biotech | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 217.74M | -3.7x | -0.08 | SEK 0.18 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Annexin Pharma | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 187.77M | -3.8x | -0.08 | SEK 26.60 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SenzaGen | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 185.88M | -10.4x | -0.39 | SEK 6.30 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Glycorex Transplantation | NGM | Healthcare | Biotechnology & Medical Research | SEK 171.11M | -17.9x | -0.27 | SEK 2.17 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dextech Medical | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 166.37M | -36.6x | SEK 9 | 11.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Alzinova | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 163.79M | -5.8x | -0.23 | SEK 1.57 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alligator Bioscience | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 150.18M | -0.3x | -0.01 | SEK 4.32 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biovica International | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 143.94M | -0.7x | -0.03 | SEK 0.64 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NextCell Pharma AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 130.11M | -2.1x | -0.07 | SEK 1.14 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lumito AB | NGM | Healthcare | Biotechnology & Medical Research | SEK 124.71M | -2.2x | 0.03 | SEK 0.45 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kancera AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 116.34M | -2.6x | -0.05 | SEK 0.96 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biosergen AS | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 115.06M | -6.8x | -0.06 | SEK 0.48 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abera Bioscience | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 111.30M | -167.4x | SEK 7.40 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.7% Upside | Upgrade to Pro+ | ||
Klaria Pharma Holding AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 110.44M | -1.6x | -0.11 | SEK 0.45 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IDL Diagnostics AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 99.06M | -2.2x | -0.15 | SEK 0.43 | -7.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Spago Nanomedical AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 91.23M | -2.9x | -0.05 | SEK 0.26 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31% Upside | Upgrade to Pro+ | |
Coegin Pharma AB | NGM | Healthcare | Biotechnology & Medical Research | SEK 73.64M | -3.6x | -0.09 | SEK 4.30 | 26.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Acousort | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 68.78M | -3.2x | -0.21 | SEK 3.25 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Modus Therapeutics Holding AB | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 68.28M | -3.4x | -0.19 | SEK 2.94 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -71.4% Downside | Upgrade to Pro+ | |
2cureX | Stockholm | Healthcare | Biotechnology & Medical Research | SEK 68.03M | -0.3x | SEK 2.70 | -6.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Chosa Oncology AB | Spotlight | Healthcare | Biotechnology & Medical Research | SEK 63.91M | -5.8x | -3.06 | SEK 0.81 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |